Sort   by:  
 Page size 
UnknownPopulation Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.
Not available
S-EPMC4486092 | biostudies-literature
UnknownValidation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
Not available
S-EPMC6267864 | biostudies-literature
UnknownEvaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients.
Not available
S-EPMC8214796 | biostudies-literature
UnknownCefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients.
Not available
S-EPMC10353438 | biostudies-literature
UnknownEvaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.
Not available
S-EPMC7478943 | biostudies-literature
UnknownInfluence of the skeletal muscle index on pharmacokinetics and toxicity of fluorouracil.
Not available
S-EPMC9939223 | biostudies-literature
UnknownUnmet information needs and knowledge gaps in cancer patients undergoing oral anticancer therapy.
Not available
S-EPMC12712599 | biostudies-literature
UnknownAdherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study.
Not available
S-EPMC3717446 | biostudies-literature
UnknownA Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.
Not available
S-EPMC4627460 | biostudies-literature
UnknownPrioritisation of Adverse Drug Events Leading to Hospital Admission and Occurring during Hospitalisation: A RAND Survey.
Not available
S-EPMC9332872 | biostudies-literature
Sort   by:  
 Page size